

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Cagle et al.

U.S. Serial No. 10/706,759

Filed: November 12, 2003

Examiner: NYA

Group Art Unit: NYA

For: "The Use of an Anti-Allergy  
Agent and a Steroid to Treat  
Nasal Conditions"

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this date:

February 6, 2004  
Date

Jeanie Burke  
Jeanie Burke

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. 1.56


Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56. Applicants submit the following patents, articles and other information listed on the attached PTO Form 1449.

Because the PTO has waived the requirement under 37 CFR 1.98(a)(2) to submit copies of each cited U.S. patent and patent application publication in all U.S. national patent applications filed after June 30, 2003, none are enclosed. Only copies of cited foreign patent documents and non-patent literature are enclosed.

Applicants request that the listed references be considered during prosecution of this application, and that the references appear among the "References Cited" on any patent issuing herefrom.



Respectfully submitted,

ALCON


2-6-04

Date

Patrick M. Ryan  
Registration No. 36,263


R&D Counsel Q-148  
Alcon Research, Ltd.  
6201 South Freeway  
Fort Worth, Texas 76134-2099  
(817) 551-3066

Attorney Docket No.: 2442

Form PTO-1449 U.S. Dept. of Commerce Patent & Trademark Office <b>LIST OF DOCUMENTS CITED BY APPLICANT</b> <div style="border: 1px solid black; border-radius: 50%; width: 100px; height: 100px; display: flex; align-items: center; justify-content: center; margin: 10px auto;"> <div style="text-align: center;">  </div> </div> (Use several sheets if necessary)		ATTY. DOCKET NO. 2442		SERIAL NO. 10/706,759			
		APPLICANT Cagle et al.					
		FILING DATE November 12, 2003		GROUP NYA			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,430,343	02/07/84	Iemura et al.	424	250	
	AB	4,871,865	10/03/89	Lever, Jr. et al.	549	354	
	AC	4,923,892	05/08/90	Lever, Jr. et al.	514	450	
	AD	5,116,863	05/26/92	Oshima et al.	514	450	
	AE	5,149,694	09/22/92	Cagle et al.	514	40	
	AF	5,192,780	03/09/93	York et al.	514	357	
	AG	5,223,493	06/29/93	Boltralik	514	180	
	AH	5,420,120	05/30/95	Boltralik	514	172	
	AI	5,441,958	08/15/95	Yanni et al.	514	253	
	AJ	5,641,805	06/24/97	Yanni et al.	514	450	
	AK	5,668,133	09/16/97	Yanni et al.	514	253	
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AL	2 387 398	03/28/02	Canada			
	AM	WO 97/01337	01/16/97	PCT			
	AN	WO 97/46243	12/11/97	PCT			
	AO	WO 01/35963	05/25/01	PCT			
	AP	WO 03/049770	06/19/03	PCT			
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	AR	Bhargava et al., "Ocular Allergic Disease," <i>Drugs of Today</i> , Vol. 34(11), pp. 957-971 (1998)					
	AS	Friedlaender et al., "The Current and Future Therapy of Allergic Conjunctivitis," <i>Current Opinion in Ophthalmology</i> , Vol. 9, pp. 54-58 (1998)					
	AT	Hochhaus et al., "binding affinities of rimexolone (ORG 6216), flunisolide and their utative metabolites for the glucocorticoid receptor of human synovial tissue," <i>Agents and Actions</i> , Vol. 30 (3/4), pp.. 377-380 (1990)					

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 U.S. Dept. of Commerce Patent & Trademark Office <b>LIST OF DOCUMENTS CITED BY APPLICANT</b> <div style="border: 1px solid black; border-radius: 50%; width: 100px; height: 100px; display: flex; align-items: center; justify-content: center; margin: 10px auto;"> <div style="text-align: center;">  </div> </div> (Use several sheets if necessary)		ATTY. DOCKET NO. 2442	SERIAL NO. 10/706,759				
APPLICANT Cagle et al.							
FILING DATE November 12, 2003		GROUP NYA					
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	BA	5,747,061	05/05/98	Amselem et al.	424	427	
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BL						
	BM						
	BN						
	BO						
	BP						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	BR	FLONASE® Nasal Spray Product Insert					
	BS	NASONEX® Nasal Spray Product Insert					
	BT	RHINOCORT AQUA™ Nasal Spray Product Insert					

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.